Boston Scientific Corp (BSX) Valuation

Based on the GoodMoat Target of $90.04, the current price of $69.78 implies a margin of safety of approximately 22.5%. According to the GoodMoat Investment Framework's valuation bands, this falls into the 'Favourable' range (20–40%), indicating the stock is priced below its estimated intrinsic value. This provides a reasonable buffer for a value investor. The primary valuation concern is the forward P/E of 35.7x, which is high relative to the sector and the company's current earnings per share of $1.94. For context, a P/E this high is typically justified only for companies with very high growth rates, and while Boston Scientific's revenue growth of 15.9% is strong, the P/E-to-growth (PEG) ratio would be above 2.2, exceeding the favourable threshold of <1.0. The free cash flow yield of 3.5% (implying a P/FCF of ~28.6x) also suggests the valuation is not cheap on a cash flow basis. The stock's quality, evidenced by solid operating margins and revenue growth, is being recognized by the market, but the valuation requires confidence in sustained high performance to be justified. The favourable margin of safety from the target price is the key supportive factor, but the elevated multiples indicate limited room for error.